- Excellent review by Bruce Booth, partner at Atlas Ventures, of 2021 Year in Biotech.
- It covers the impact of the pandemic (both good and bad), current pipeline (5,000 compounds, $180bn of R&D spend), policy picture, the abundance of capital against constrained talent (here and 25:30) and so much more!
